Activation of Dendritic Cells by the Novel Toll-Like Receptor 3 Agonist RGC100
Figure 4
Inhibition of activation of JAWS II DCs by RGC100 using siRNA targeting TLR3. Cells were treated with siRNA targeting TLR3, then incubated with RGC100 at the indicated concentrations. RNA was extracted and supernatant was harvested. (a) Relative expression of TLR3 mRNA in cells treated with siRNA targeting TLR3 or with a nontargeting siRNA (NC siRNA). mRNA levels were normalized to β-actin mRNA. rE, relative expression. (b) Secretion of IL-6 was measured by ELISA. Values shown are mean ± SEM of two independent measures. Negative control consists of supernatant of cells incubated in the absence of RGC100 and siRNA. Values of negative control have been subtracted from the values represented on the graph.
